Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843317 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
A Phase 1 study of RSV Infection, sponsored by Clover Biopharmaceuticals USA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 5
- Study locations
NCT06843317 is a Phase 1 study of RSV Infection that is actively recruiting participants, run by Clover Biopharmaceuticals USA. The registered enrollment target is 160 participants, below the 727-participant average among 8 other RSV Infection trials with a reported enrollment target (78% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06843317, a Phase 1 study of RSV Infection, is actively recruiting participants, sponsored by Clover Biopharmaceuticals USA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 5
- Study locations
Study Summary
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Conditions Studied
Interventions
- BIOLOGICAL Candidate vaccine, SCB-1019T
- BIOLOGICAL AREXVY
- OTHER placebo
Study Locations (5)
Arizona
- AMR Phoenix - Phoenix
Florida
- AMR Fort Myers - Fort Myers
Kentucky
- AMR Lexington - Lexington
Missouri
- AMR Kansas City - Kansas City
Tennessee
- Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2026-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06843317
The ClinicalTrials.gov registry entry for NCT06843317 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 8 other RSV Infection trials with a reported enrollment target (78% lower). The listed sponsor is Clover Biopharmaceuticals USA, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 3 interventions - of which Candidate vaccine, SCB-1019T is the first listed.
NCT06843317 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06843317 about?
NCT06843317 is a clinical study titled "Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults". CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
What is the current status of trial NCT06843317?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-03-21. Estimated completion is 2026-06-03.
What conditions does trial NCT06843317 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT06843317?
The interventions under investigation include: Candidate vaccine, SCB-1019T (BIOLOGICAL), AREXVY (BIOLOGICAL), placebo (OTHER).
Who is sponsoring clinical trial NCT06843317?
This trial is sponsored by Clover Biopharmaceuticals USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843317 being conducted?
This trial has 5 study locations across Arizona, Florida, Kentucky, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.